Interventional procedure overview of transcatheter tricuspid valve leaflet repair for tricuspid regurgitation

Existing assessments of this procedure

The Canadian Agency for Drugs and Technologies in Health (CADTH) published a rapid response report in 2020 on 'Transcatheter Mitral Valve Repair for Tricuspid Regurgitation with or without Mitral Regurgitation'. The report concluded:

'Overall, compared to pre-procedure, patients [who had] MitraClip for the treatment of tricuspid regurgitation or both tricuspid and mitral regurgitation had significantly improved tricuspid regurgitation grade, New York Heart Association functional class, edema, and ascites at follow-up. Across four studies that reported on procedural success, the percentage of patients with procedural success ranged from 92% to 97%. There was no statistically significant difference in quality of life between baseline and follow-up in the three studies that measured this outcome. Four of the studies showed statistically significant improvement in the six-minute walking distance at one month or six months, in patients who received tricuspid valve (TV) repair or both TV and mitral valve (MV) repair. One study observed a numerical (but not significant) improvement in the six-minute walking distance from baseline to one-year follow up. For heart failure severity when comparing baseline and follow up, two studies found significant improvement; two studies found no statistically significant difference; and one study demonstrated a statistically significant improvement in patients who received TV-only repair but no significant difference in patients who received both TV and MV repair. The mortality incidence after the procedure was 4.7% to 7% across the included studies.

The findings summarized in this report have a high degree of uncertainty due to the limitations of the included studies (e.g., a total of 209 patients in single-arm studies, longest follow-up duration of one year).' (Li, 2020)